Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.67 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 7/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | KAT7 | O95251 | 1/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870792 | 1.00 | ACKR3 (0.67) | ACKR3KDM1AUSP30HTR6BCHE | |
| SCHEMBL21605820 | 0.89 | ACKR3 (0.57) | ACKR3KDM1AHTR6BCHEIRAK1 | |
| SCHEMBL16333276 | 0.89 | ACKR3 (0.57) | ACKR3KDM1AHTR6BCHEIRAK1 | |
| SCHEMBL5870872 | 0.89 | ACKR3 (0.57) | ACKR3KDM1AUSP30HTR6BCHE | |
| SCHEMBL21605819 | 0.89 | ACKR3 (0.57) | ACKR3KDM1AHTR6BCHEIRAK1 | |
| SCHEMBL5870674 | 0.88 | NAMPT (0.62) | ACKR3USP30KDM4EPKMNAMPT | |
| SCHEMBL5870688 | 0.87 | ACKR3 (0.54) | ACKR3KDM1AUSP30HTR6BCHE | |
| SCHEMBL3087666 | 0.85 | KDM4E (0.70) | KDM1AKDM4EPKMGPR119TGFBR1 | |
| SCHEMBL19378006 | 0.85 | ACKR3 (0.53) | ACKR3KDM1AUSP30HTR6BCHE | |
| SCHEMBL5870922 | 0.84 | ACKR3 (0.58) | ACKR3KDM1AUSP30HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885KDM1A 4501/4885USP30 3782/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885KDM1A 4501/4885USP30 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.